Allergy Therapeutics PLC has announced the appointment of Shaun Furlong as an Executive Director of the Company, effective from 8th March 2024. Furlong, who previously served as the Group's Chief Financial Officer (CFO) and Group Financial Controller, brings significant financial experience from senior roles in various sectors. Peter Jensen, Chairman of Allergy Therapeutics, expressed confidence in Furlong's capabilities, citing his professionalism, strong financial acumen, and range of experience. Furlong himself expressed delight in taking on an expanded leadership role as an Executive Director and looks forward to working alongside other members of the Board.

Shaun Antony Furlong, aged 48, holds an interest in 1,500 ordinary shares in the Company. In the previous five years, he was a director of SAF Management Services Limited. The Company confirmed that there is no other information in relation to Shaun's appointment that is required to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information, interested parties can contact Allergy Therapeutics or Panmure Gordon (Nominated Adviser and Broker). Additionally, ICR Consilium is available for media inquiries.

Allergy Therapeutics PLC is an integrated commercial biotechnology company specializing in allergy vaccines.